DE60118590D1 - Medizinische zusammensetzungen als begleittherapie gegen krebs - Google Patents

Medizinische zusammensetzungen als begleittherapie gegen krebs

Info

Publication number
DE60118590D1
DE60118590D1 DE60118590T DE60118590T DE60118590D1 DE 60118590 D1 DE60118590 D1 DE 60118590D1 DE 60118590 T DE60118590 T DE 60118590T DE 60118590 T DE60118590 T DE 60118590T DE 60118590 D1 DE60118590 D1 DE 60118590D1
Authority
DE
Germany
Prior art keywords
ring
salt
substituent group
against cancer
therapy against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60118590T
Other languages
English (en)
Other versions
DE60118590T2 (de
Inventor
Yoichi Ozawa
Kentaro Yoshimatsu
Junko Kai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of DE60118590D1 publication Critical patent/DE60118590D1/de
Application granted granted Critical
Publication of DE60118590T2 publication Critical patent/DE60118590T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
DE60118590T 2000-10-31 2001-10-31 Medizinische zusammensetzungen als begleittherapie gegen krebs Expired - Lifetime DE60118590T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000333952 2000-10-31
JP2000333952 2000-10-31
PCT/JP2001/009563 WO2002036117A1 (fr) 2000-10-31 2001-10-31 Compositions medicinales destinees a etre utilise de maniere concomitante comme agent anticancereux

Publications (2)

Publication Number Publication Date
DE60118590D1 true DE60118590D1 (de) 2006-05-18
DE60118590T2 DE60118590T2 (de) 2007-01-18

Family

ID=18809950

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60118590T Expired - Lifetime DE60118590T2 (de) 2000-10-31 2001-10-31 Medizinische zusammensetzungen als begleittherapie gegen krebs

Country Status (12)

Country Link
US (3) US20040002505A1 (de)
EP (1) EP1331005B1 (de)
JP (1) JP4167898B2 (de)
KR (1) KR100829875B1 (de)
CN (1) CN1196484C (de)
AT (1) ATE322264T1 (de)
AU (2) AU1099302A (de)
CA (1) CA2427617C (de)
DE (1) DE60118590T2 (de)
NZ (1) NZ524975A (de)
TW (1) TWI283575B (de)
WO (1) WO2002036117A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1415987B1 (de) 2000-10-20 2007-02-28 Eisai R&D Management Co., Ltd. Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen
JPWO2004080462A1 (ja) * 2003-03-10 2006-06-08 エーザイ株式会社 ｃ−Ｋｉｔキナーゼ阻害剤
EP1622624B1 (de) * 2003-05-08 2007-12-26 Eisai R&D Management Co., Ltd. Medizinische zusammensetzungen enthaltend n-(3-chloro-1h-indol-7-yl)-4-sulfamoylbenzensulfonamid und weitere cytostatika
EP1666463B1 (de) * 2003-09-10 2010-11-03 Eisai R&D Management Co., Ltd. Kristall einer sulfonamidhaltigen indolverbindung und verfahren zu dessen herstellung
WO2005026119A1 (ja) * 2003-09-10 2005-03-24 Eisai Co., Ltd. スルホンアミド含有インドール化合物の製造方法
CN101337930B (zh) 2003-11-11 2010-09-08 卫材R&D管理有限公司 脲衍生物的制备方法
NZ548212A (en) * 2003-12-29 2010-07-30 Sepracor Inc Pyrrole and pyrazole DAAO inhibitors
AU2005216898A1 (en) * 2004-02-26 2005-09-09 The Penn State Research Foundation Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor
EP1797881B1 (de) 2004-09-17 2009-04-15 Eisai R&D Management Co., Ltd. Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
EP1859797A4 (de) * 2005-02-28 2011-04-13 Eisai R&D Man Co Ltd Neue gleichzeitige verwendung einer sulfonamid-verbindung und eines mittels gegen krebs
CN1313104C (zh) * 2005-05-27 2007-05-02 中国科学院南海海洋研究所 一种具有柴胡和多霉素协同作用的抗癌药物组合物
EP1904066B1 (de) 2005-07-06 2018-05-23 Sunovion Pharmaceuticals Inc. KOMBINATIONEN VON ESZOPICLON UND TRANS-4-(3,4-DICHLORPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE OR TRANS-4-(3,4-DICHLORPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPHTHALINAMIN ZUR BEHANDLUNG DER MENOPAUSE, Perimenopause UND VON KOGNITIVEN STÖRUNGEN
JP5066446B2 (ja) * 2005-08-01 2012-11-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を予測する方法
EP2281901B1 (de) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Pharmazeutische anti-tumor Zusammensetzung mit Angiogeneseinhibitoren
JP5209966B2 (ja) * 2005-09-01 2013-06-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 崩壊性の改善された医薬組成物の製造方法
US20090053236A1 (en) * 2005-11-07 2009-02-26 Eisai R & D Management Co., Ltd. USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
WO2007061130A1 (ja) * 2005-11-22 2007-05-31 Eisai R & D Management Co., Ltd. 多発性骨髄腫に対する抗腫瘍剤
JP5432526B2 (ja) 2006-01-06 2014-03-05 サノビオン ファーマシューティカルズ インク モノアミン再取り込み阻害剤としてのシクロアルキルアミン
KR101381768B1 (ko) * 2006-01-06 2014-04-07 선오비온 파마슈티컬스 인코포레이티드 테트랄론-기재 모노아민 재흡수 저해제
AU2007233041B2 (en) 2006-03-31 2013-05-02 Sepracor Inc. Preparation of chiral amides and amines
EP2036557B1 (de) * 2006-05-18 2015-10-21 Eisai R&D Management Co., Ltd. Antitumorales mittel gegen schilddrüsenkrebs
JPWO2008001956A1 (ja) * 2006-06-29 2009-12-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝線維症治療剤
US20080058395A1 (en) * 2006-06-30 2008-03-06 Sepracor Inc. Fused heterocyclic inhibitors of D-amino acid oxidase
US7579370B2 (en) * 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US7884124B2 (en) * 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
JP2010516697A (ja) * 2007-01-18 2010-05-20 セプラコール インク． Ｄ−アミノ酸オキシダーゼ阻害剤
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
JP5319306B2 (ja) 2007-01-29 2013-10-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌治療用組成物
NZ580429A (en) 2007-05-31 2012-04-27 Sepracor Inc Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
MX2010008187A (es) * 2008-01-29 2010-08-10 Eisai R&D Man Co Ltd Uso combinado de inhibidor de angiogenesis y taxano.
CN101584696A (zh) * 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
US20100120740A1 (en) * 2008-08-07 2010-05-13 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
WO2011017634A2 (en) * 2009-08-07 2011-02-10 Sepracore Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
CN102958523B (zh) 2010-06-25 2014-11-19 卫材R&D管理有限公司 使用具有激酶抑制作用的组合的抗肿瘤剂
WO2012144463A1 (ja) 2011-04-18 2012-10-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
BR112015009004A8 (pt) 2012-12-21 2021-07-20 Eisai R&D Man Co Ltd forma amorfa de derivado de quinolina e método de produção da mesma
MX368099B (es) 2013-05-14 2019-09-19 Eisai R&D Man Co Ltd Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
ES2680444T3 (es) 2014-01-17 2018-09-07 Oncoral Pharma Aps Forma de dosificación oral sólida de irinotecán para el tratamiento del cáncer
HRP20221047T1 (hr) 2014-08-28 2022-11-11 Eisai R&D Management Co., Ltd. Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju
JP7113619B2 (ja) * 2014-12-09 2022-08-05 イプセン バイオファーム リミティド リポソーマルイリノテカンによる乳がんの治療
CN107427505A (zh) 2015-02-25 2017-12-01 卫材R&D管理有限公司 用于抑制喹啉衍生物的苦味的方法
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
US11369623B2 (en) 2015-06-16 2022-06-28 Prism Pharma Co., Ltd. Anticancer combination of a CBP/catenin inhibitor and an immune checkpoint inhibitor
WO2017031442A1 (en) 2015-08-20 2017-02-23 Merrimack Pharmaceuticals, Inc. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
CA2993451A1 (en) 2015-08-21 2017-03-02 Ipsen Biopharm Ltd. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
US11071726B2 (en) 2016-11-02 2021-07-27 Ipsen Biopharm Ltd. Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3545461B2 (ja) * 1993-09-10 2004-07-21 エーザイ株式会社 二環式ヘテロ環含有スルホンアミド誘導体
AU683492B2 (en) * 1993-09-10 1997-11-13 Eisai R&D Management Co., Ltd. Bicyclic heterocyclic sulfonamide and sulfonic ester derivatives
JPH09208571A (ja) * 1996-02-02 1997-08-12 Takeda Chem Ind Ltd アルキリデンシクロヘキサン誘導体
JP2000143635A (ja) * 1998-06-10 2000-05-26 Takeda Chem Ind Ltd 血管新生阻害剤
JP2000247949A (ja) 1999-02-26 2000-09-12 Eisai Co Ltd スルホンアミド含有インドール化合物
US6911306B1 (en) * 1999-10-18 2005-06-28 Emory University TMS1 compositions and methods of use
AU7013401A (en) * 2000-06-22 2002-01-02 Univ Iowa Res Found Methods for enhancing antibody-induced cell lysis and treating cancer

Also Published As

Publication number Publication date
NZ524975A (en) 2004-11-26
TWI283575B (en) 2007-07-11
JP4167898B2 (ja) 2008-10-22
US20030215523A1 (en) 2003-11-20
EP1331005A4 (de) 2004-12-22
KR20030046475A (ko) 2003-06-12
JPWO2002036117A1 (ja) 2004-03-11
KR100829875B1 (ko) 2008-05-16
EP1331005B1 (de) 2006-04-05
EP1331005A1 (de) 2003-07-30
US20040224972A1 (en) 2004-11-11
AU1099302A (en) 2002-05-15
US20040002505A1 (en) 2004-01-01
ATE322264T1 (de) 2006-04-15
CN1196484C (zh) 2005-04-13
CA2427617C (en) 2009-10-06
WO2002036117A1 (fr) 2002-05-10
CA2427617A1 (en) 2003-04-29
DE60118590T2 (de) 2007-01-18
CN1473041A (zh) 2004-02-04
AU2002210993B2 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
DE60118590D1 (de) Medizinische zusammensetzungen als begleittherapie gegen krebs
DE60227794D1 (de) Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
MXPA02011974A (es) Derivados de quinazolina sustituidos y su uso como inhibidores.
SE0102764D0 (sv) Compounds
BR0206955A (pt) Ligantes de receptores de canabinóides
DE60118225D1 (de) Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
ATE503746T1 (de) Neue imidazolidinderivate
IL174665A0 (en) Heterocyclic compounds which act as p-glycoprotein inhibitors and pharmaceutical compositions containing the same
DE60330407D1 (de) Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
DE60115465D1 (de) Immunoregulierende verbindungen, deren derivate und ihre verwendung
AR019790A2 (es) Compuestos derivados de la eritromicina, composiciones que los contienen. uso para preparar un medicamento
ATE450499T1 (de) Durch enzyme spaltbare prodrugs von substituierten stickstoff-lost-derivaten
DE69023928T2 (de) DIAMINVERBINDUNGEN UND ARZNEIMITTEL GEGEN CEREBRALE STöRUNGEN DIE DIESE ENTHALTEN.
NO20025035D0 (no) Oksadiazolderivater som har anticancer-effekter
FI935800A0 (fi) Antidepressiva och mot Parkisons sjukdom verksamma foereningar
BRPI0417007A (pt) agentes antivirais de diazaindol-dicarbonil-piperazinila
CA2535210A1 (en) Novel farnesyl protein transferase inhibitors as antitumor agents
ATE140458T1 (de) Imidazole derivate und diese enthaltende arzneimittel
HUP0402341A2 (hu) Szubsztituált tiazol-2-ilaminokat tartalmazó készítmények rák kezelésére
DE69931378D1 (de) Chinazolin derivate und therapeutische verwendungen davon
ATE320795T1 (de) Oberflächenaktive verbindungen und ihre anwendungen
PT1351954E (pt) Derivados 4-heterociclil-quinolina e quinazolina inibidores da farnesil-transferase
MA30179B1 (fr) Derives de 2-carbamide-4-phenylthiazole, leur preparation et leur application en therapeutique.
EA200701881A1 (ru) 1,3-тиазол-5-карбоксамиды, используемые в качестве противораковых химиотерапевтических агентов
TW200509915A (en) Novel oxazoles, their manufacture and use as pharmaceutical agents

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: EISAI R&D MANAGEMENT CO., LTD., TOKYO, JP